Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

DiaMedica Therapeutics (DMAC) EPS (Basic) (2018 - 2026)

DiaMedica Therapeutics filings provide 9 years of EPS (Basic) readings, the most recent being -$0.19 for Q1 2026.

  • Quarterly EPS (Basic) fell 5.56% to -$0.19 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$0.71 through Mar 2026, down 10.94% year-over-year, with the annual reading at -$0.7 for FY2025, 16.67% down from the prior year.
  • EPS (Basic) hit -$0.19 in Q1 2026 for DiaMedica Therapeutics, down from -$0.17 in the prior quarter.
  • Across five years, EPS (Basic) topped out at -$0.12 in Q3 2022 and bottomed at -$0.2 in Q1 2023.
  • Average EPS (Basic) over 5 years is -$0.15, with a median of -$0.15 recorded in 2024.
  • The largest annual shift saw EPS (Basic) skyrocketed 33.33% in 2022 before it crashed 53.85% in 2023.
  • DiaMedica Therapeutics' EPS (Basic) stood at -$0.14 in 2022, then rose by 0.0% to -$0.14 in 2023, then fell by 28.57% to -$0.18 in 2024, then increased by 5.56% to -$0.17 in 2025, then decreased by 11.76% to -$0.19 in 2026.
  • Per Business Quant, the three most recent readings for DMAC's EPS (Basic) are -$0.19 (Q1 2026), -$0.17 (Q4 2025), and -$0.17 (Q3 2025).